Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ureña P[au]:

Search results

Items: 1 to 50 of 100

1.

The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Youssef B, Yan C, Dimitri TB, Najeh EE, Ureña P, Sandra B, Christian C, Bertrand D, Denis F, Gabriel C, Sophie L.

Toxins (Basel). 2019 May 17;11(5). pii: E279. doi: 10.3390/toxins11050279.

2.

Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders.

Bover J, Ureña P, Aguilar A, Mazzaferro S, Benito S, López-Báez V, Ramos A, daSilva I, Cozzolino M.

Calcif Tissue Int. 2018 Aug;103(2):111-124. doi: 10.1007/s00223-018-0399-z. Epub 2018 Feb 14.

PMID:
29445837
3.

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26.

4.

Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases.

Mageau A, Guigonis V, Ratzimbasafy V, Bardin T, Richette P, Urena P, Ea HK.

Joint Bone Spine. 2017 May;84(3):341-344. doi: 10.1016/j.jbspin.2016.10.009. Epub 2016 Dec 7.

PMID:
27955821
5.

Dementia is a major risk factor for hip fractures in patients with chronic kidney disease.

Maravic M, Ostertag A, Urena P, Cohen-Solal M.

Osteoporos Int. 2016 Apr;27(4):1665-1669. doi: 10.1007/s00198-015-3429-y. Epub 2015 Nov 20.

PMID:
26588907
6.

Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Bover J, Ureña P, Ruiz-García C, daSilva I, Lescano P, del Carpio J, Ballarín J, Cozzolino M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):161-74. doi: 10.2215/CJN.01760215. Epub 2015 Jul 29. Review.

7.

Adynamic bone disease: from bone to vessels in chronic kidney disease.

Bover J, Ureña P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, Bosch RJ.

Semin Nephrol. 2014 Nov;34(6):626-40. doi: 10.1016/j.semnephrol.2014.09.008. Review.

PMID:
25498381
8.

Impact of a novel community-based lifestyle intervention program on type 2 diabetes and cardiovascular risk in a resource-poor setting in the Dominican Republic.

West-Pollak A, Then EP, Podesta C, Hedelt A, Perry ML, Izarnotegui WV, Perez M, Villegas A, Baez NI, Bassa R, Mendez G, Hernandez K, Lim DS, Urena P, Taylor AM.

Int Health. 2014 Jun;6(2):118-24. doi: 10.1093/inthealth/iht039. Epub 2014 Feb 3.

PMID:
24497608
9.

The Colibri heart valve: theory and practice in the achievement of a low-profile, pre-mounted, pre-packaged TAVI valve.

Fish RD, Paniagua D, Ureña P, Chevalier B.

EuroIntervention. 2013 Sep 10;9 Suppl:S111-4. doi: 10.4244/EIJV9SSA23. No abstract available.

PMID:
24025948
10.

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.

Zitt E, Fouque D, Jacobson SH, Malberti F, Ryba M, Ureña P, Rix M, Dehmel B, Manamley N, Vervloet M.

Clin Kidney J. 2013 Jun;6(3):287-294. Epub 2013 Apr 11.

11.

[Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience].

Ureña P, Fouque D, Brunet P, Touam M, Réglier JC.

Nephrol Ther. 2012 Dec;8(7):527-33. doi: 10.1016/j.nephro.2012.05.002. Epub 2012 Sep 25. French.

PMID:
23018042
12.

Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.

Frazão JM, Messa P, Mellotte GJ, Geiger H, Hagen EC, Quarles LD, Kerr PG, Baños A, Dehmel B, Urena P.

Clin Nephrol. 2011 Sep;76(3):233-43.

PMID:
21888861
13.

"Real-World" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study.

Vervloet M, Bencova V, Malberti F, Ashman N, Os I, Saha H, Ureña P, Zitt E, Rix M, Ryba M, Fouque D, Dehmel B, Petavy F, Jacobson SH.

Clin Nephrol. 2010 Sep;74(3):198-208.

PMID:
20860904
14.

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.

Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM, Vanholder R.

Nephrol Dial Transplant. 2010 Dec;25(12):3823-31. doi: 10.1093/ndt/gfq513. Epub 2010 Sep 9. Review.

PMID:
20829401
15.

2009 EANM parathyroid guidelines.

Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D; Parathyroid Task Group of the EANM.

Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1201-16. doi: 10.1007/s00259-009-1131-z.

PMID:
19471928
16.

Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality.

Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Ureña P, Iñigo P, Minutolo R, Haviv YS, Yeates K, Agüera ML, MacRae JM, Levin A.

Clin J Am Soc Nephrol. 2009 Jul;4(7):1176-82. doi: 10.2215/CJN.04920908. Epub 2009 May 7.

17.

Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.

Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D.

Nephrol Dial Transplant. 2009 Sep;24(9):2852-9. doi: 10.1093/ndt/gfp144. Epub 2009 Apr 15.

PMID:
19369690
19.

Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients.

Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, Mamzer-Bruneel MF, Urena P, Legendre C, Friedlander G, Prié D.

Kidney Int. 2009 Mar;75(6):646-51. doi: 10.1038/ki.2008.549. Epub 2008 Oct 15.

20.

Pitfalls of measuring total blood calcium in patients with CKD.

Gauci C, Moranne O, Fouqueray B, de la Faille R, Maruani G, Haymann JP, Jacquot C, Boffa JJ, Flamant M, Rossert J, Urena P, Stengel B, Souberbielle JC, Froissart M, Houillier P; NephroTest Study Group.

J Am Soc Nephrol. 2008 Aug;19(8):1592-8. doi: 10.1681/ASN.2007040449. Epub 2008 Apr 9.

21.

Sodium thiosulfate as first-line treatment for calciphylaxis.

Ackermann F, Levy A, Daugas E, Schartz N, Riaux A, Derancourt C, Urena P, Lebbé C.

Arch Dermatol. 2007 Oct;143(10):1336-7; author reply 1338. No abstract available.

PMID:
17938357
22.

[Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].

Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC; Groupe de l'étude NESP 20000117.

Nephrol Ther. 2006 Sep;2(4):191-9. Epub 2006 Aug 17. French.

PMID:
16966064
23.

Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression.

Rivet J, Lebbé C, Urena P, Cordoliani F, Martinez F, Baglin AC, Aubert P, Aractingi S, Ronco P, Fournier P, Janin A.

Arch Dermatol. 2006 Jul;142(7):900-6.

PMID:
16847207
24.

[Calcimimetics, mechanisms of action and therapeutic applications].

Ureña P, Legoupil N, de Vernejoul MC.

Presse Med. 2005 Sep 10;34(15):1095-100. Review. French.

PMID:
16334889
25.

[Progress in the treatment of some kidney disorders].

Vanhille P, Deray G, Ureña P.

Presse Med. 2005 Sep 24;34(16 Pt 2):1193-6. Review. French. No abstract available.

PMID:
16208272
26.

Recent findings in phosphate homeostasis.

Prié D, Beck L, Urena P, Friedlander G.

Curr Opin Nephrol Hypertens. 2005 Jul;14(4):318-24. Review.

PMID:
15930998
27.

Quiz page. Subcutaneous sarcoidosis.

Ureña P.

Am J Kidney Dis. 2005 Jan;45(1):A45, e1-2. No abstract available.

PMID:
15696432
28.

[Clinical use of calcimimetics in the treatment of hyperparathyroidisms].

Urena P.

Med Sci (Paris). 2004 Nov;20(11):973-8. French.

29.

[Recommendations for prevention of contrast-media induced nepropathy].

Arkouche W, Brillet G, Cao-Huu T, Issad B, Siohan P, Souid M, Stroumza P, Tollis F, Urena P, Pengloan J; Commission de Dialyse--Société de Néphrologie.

Nephrologie. 2004;25(4):149-50. French. No abstract available.

PMID:
15291145
30.

[Information and recommendations to patients with arteriovenous fistula].

Arkouche W, Brillet G, Cao-Huu T, Issad B, Siohan P, Souid M, Stroumza P, Tollis F, Urena P, Pengloan J; Commission de Dialyse--Société de Néphrologie.

Nephrologie. 2004;25(4):147. French. No abstract available.

PMID:
15291144
31.

[Information and recommendations to patients to preserve vessels for vascular access].

Arkouche W, Brillet G, Cao-Huu T, Issad B, Siohan P, Souid M, Stroumza P, Tollis F, Urena P, Pengloan J; Commission de Dialyse--Société de Néphrologie.

Nephrologie. 2004;25(4):145. French. No abstract available.

PMID:
15291143
32.

PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy.

Schindler S, Mannstadt M, Urena P, Segre GV, Stein G.

Clin Nephrol. 2004 Apr;61(4):253-60.

PMID:
15125031
33.

Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients.

Ureña P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, de Vernejoul MC.

Nephrol Dial Transplant. 2003 Nov;18(11):2325-31.

PMID:
14551361
34.

Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.

Ureña P.

Artif Organs. 2003 Sep;27(9):759-64. Review.

PMID:
12940896
35.

[The PTH/PTHrP receptor: biological implications].

Ureña P.

Nefrologia. 2003;23 Suppl 2:12-7. Review. Spanish.

36.

Calcimimetic agents: review and perspectives.

Ureña P, Frazão JM.

Kidney Int Suppl. 2003 Jun;(85):S91-6. Review.

PMID:
12753275
37.

[Parathyroid gland, calcium receptor and calcimimetics].

Ureña P.

Nephrologie. 2002;23(4):151-64. Review. French.

PMID:
12125321
38.

Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia.

Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Arnold A.

J Am Soc Nephrol. 2002 Jun;13(6):1490-8.

39.

Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol.

Ureña P, Bernard-Poenaru O, Cohen-Solal M, de Vernejoul MC.

Clin Nephrol. 2002 Apr;57(4):261-73.

PMID:
12005242
40.
41.

Parathyroid gland radionuclide scanning--methods and indications.

Hindié E, de LV, Mellière D, Jeanguillaume C, Urena P, Perlemuter L, Askienazy S.

Joint Bone Spine. 2002 Jan;69(1):28-36. Review.

PMID:
11858353
42.

[Arterial hypotension in dialysis].

Ureña P.

Nephrologie. 2001;22(3):105-13. Review. French.

PMID:
11436665
43.

[Biological markers of bone turnover in renal failure].

Ureña P.

Ann Biol Clin (Paris). 2001 May-Jun;59(3):313-6. French. No abstract available.

44.

Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning.

Hindié E, Mellière D, Jeanguillaume C, Ureña P, deLabriolle-Vaylet C, Perlemuter L.

Arch Surg. 2000 Dec;135(12):1461-8.

PMID:
11115353
45.

Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia.

Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Pike JW, Arnold A.

J Clin Endocrinol Metab. 2000 Feb;85(2):868-72.

PMID:
10690903
46.

Technetium-99m-sestamibi and iodine-123 subtraction scanning in primary and secondary hyperparathyroidism.

Hindié E, Urena P, Melliere D, Jeanguillaume C, Menoyo-Calonge V, Remy P, Galle P, Perlemuter L.

Adv Nephrol Necker Hosp. 1999;29:221-40. Review. No abstract available.

PMID:
10561747
47.

Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors.

Ureña P, Malergue MC, Goldfarb B, Prieur P, Guédon-Rapoud C, Pétrover M.

Nephrologie. 1999;20(4):217-25.

PMID:
10480155
48.

Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism.

Hindié E, Urenã P, Jeanguillaume C, Mellière D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P.

Lancet. 1999 Jun 26;353(9171):2200-4.

PMID:
10392985
49.

Circulating biochemical markers of bone remodeling in uremic patients.

Ureña P, De Vernejoul MC.

Kidney Int. 1999 Jun;55(6):2141-56. Review.

50.

Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement.

Ureña PE, Lamas GA, Mitchell G, Flaker GC, Smith SC Jr, Wackers FJ, McEwan P, Pfeffer MA.

J Am Coll Cardiol. 1999 Jan;33(1):180-5.

Supplemental Content

Support Center